UBS Group
CNCE

UBS Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

UBS Group’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$5K – 10074
2021
Q1 		$5K Buy
+1,000
New +$8.08K ﹤0.01% 8363

UBS Group's CNCE Position: Q1 2023 in Review

UBS Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 7,301 shares — an estimated $42.6K sold.

UBS Group first reported a position in CNCE in Q4 2014 and held it in 33 quarters. The position peaked at $7.58M in Q4 2017. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

  • UBS Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • UBS Group sold 7,301 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $42.6K.
  • UBS Group first reported a position in Concert Pharmaceuticals, Inc. in Q4 2014 and held it in 33 quarters.
  • UBS Group's Concert Pharmaceuticals, Inc. position peaked at $7.58M in Q4 2017.
  • 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.